Latest Intelligence on Cardiovascular and Diabetes in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Acomplia's EU suspension dispels illusion of blockbuster future

The EMEA has suspended Acomplia due to the risk of serious psychiatric disorders. The anti-obesity agent had been promised a sure success by numerous analysts, as it addressed indications beyond obesity. However, Acomplia failed to win approval in the US, and just two years after the EU approval its sales have been completely halted, leaving the potentially vast anti-obesity market bare again.

Published By Datamonitor
24 Oct 2008
Expert View
Expert View

Actos suspension could shake up a market already in transition

Takeda's antidiabetic drug Actos has been suspended in France and Germany following study findings which show that it is associated with an increased risk of bladder cancer. Will other countries follow and how will this impact the oral antidiabetics market?

Published By Datamonitor
13 Jun 2011
ResearchWire
ResearchWire

Acute stroke: AstraZeneca drug candidate offers blockbuster potential

Published By Datamonitor
31 Aug 2006
CommentWire
CommentWire

AHP/Bayer: Baycol unlikely to mirror fen-phen

Published By Datamonitor
24 Oct 2001
Expert View
Expert View

Amylin's choice of ally for exenatide will be crucial in the wake of its split from Lilly

Having announced an end to its co-development and marketing deal with Eli Lilly covering exenatide antidiabetic products, Amylin is now looking for a bigger partner to drive sales of Byetta and the new once-weekly formulation Bydureon. Datamonitor believes that several major pharmaceutical players meet the criteria to become a suitable ally for the company in its ongoing development of exenatide.

Published By Datamonitor
11 Nov 2011
ResearchWire
ResearchWire

Antiarrhythmics market: new product launches to reinvigorate growth

Published By Datamonitor
21 Jul 2006
ResearchWire
ResearchWire

Antihypertensives: ARBs at the heart of the market

Published By Datamonitor
27 Mar 2006
ResearchWire
ResearchWire

Antihypertensives: mature pipeline reflects market

Published By Datamonitor
01 Aug 2007
ResearchWire
ResearchWire

Antithrombotic market: novel agents will dampen generic incursion

Published By Datamonitor
15 Jan 2007
ResearchWire
ResearchWire

Antithrombotics: blockbuster potential for novel anticoagulants

Published By Datamonitor
31 May 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.